Current pharmacotherapy for the treatment of crescentic glomerulonephritis

Bibliography

• THE RENAL ASSOCIATION: The UK Renal Registry 2004, Chapter 5, Table 5.8. Ansell D, Feest T (Eds), UK Renal Registry, Bristol, UK (2006).
   Google Scholar
• JENNETTE JC: Rapidly progressive crescentic glomerulonephritis. Kidney Int. (2003) 63:1164-1177.
   PubMed Web of Science ®Google Scholar
• MULLER KOBOLD AC, VAN DER GELD YM, LIMBURG PC, TERVAERT JW, KALLENBERG CG: Pathophysiology of ANCA-associated glomerulonephritis. Nephrol. Dial. Transplant. (1999) 14:1366-1375.
   PubMed Web of Science ®Google Scholar
• LANGFORD CA, BALOW JE: New insights into the immunopathogenesis and treatment of small vessel vasculitis of the kidney. Curr. Opin. Nephrol. Hypertens. (2003) 12:267-272.
   PubMed Web of Science ®Google Scholar
• XIAO H, HEERINGA P, HU P et al.: Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest. (2002) 110:955-963.
   PubMed Web of Science ®Google Scholar
• LITTLE MA, BHANGAL G, SMYTH CL et al.: Therapeutic effect of anti-TNF-α antibodies in an experimental model of anti-neutrophil cytoplasm antibody- associated systemic vasculitis. J. Am. Soc. Nephrol. (2006) 17:160-169.
   PubMed Web of Science ®Google Scholar
• JAYNE DR: Conventional treatment and outcome of Wegener’s granulomatosis and microscopic polyangiitis. Cleve. Clin. J. Med. (2002) 69(Suppl. 2):SII110-SII115.
   PubMedGoogle Scholar
• TESAR V, RIHOVA Z, JANCOVA E, RYSAVA R, MERTA M: Current treatment strategies in ANCA-positive renal vasculitis-lessons from European randomized trials. Nephrol. Dial. Transplant. (2003) 18(Suppl. 5):v2-v4.
   PubMedGoogle Scholar
• DE GROOT K, ADU D, SAVAGE CO: The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol. Dial. Transplant. (2001) 16:2018-2027.
   PubMed Web of Science ®Google Scholar
• DE GROOT K, JAYNE DR, TESAR V, SAVAGE COS: European, multicenter randomised controlled trial of daily oral versus pulse cyclophosphamide for induction of remission in ANCA-associated systemic vasculitis. J. Am. Soc. Nephrol. (2005) 16:7A (Abstract).
   Google Scholar
• DE GROOT K, RASMUSSEN N, BACON PA et al.: Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. (2005) 52:2461-2469.
   PubMed Web of Science ®Google Scholar
• JAYNE D, RASMUSSEN N, ANDRASSY K et al.: A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. (2003) 349:36-44.
   PubMed Web of Science ®Google Scholar
• BENENSON E, FRIES JW, HEILIG B, POLLOK M, RUBBERT A: High-dose azathioprine pulse therapy as a new treatment option in patients with active Wegener’s granulomatosis and lupus nephritis refractory or intolerant to cyclophosphamide. Clin. Rheumatol. (2005) 24:251-257.
   PubMed Web of Science ®Google Scholar
• COLE E, CATTRAN D, MAGIL A et al.: A prospective randomized trial of plasma exchange as additive therapy in idiopathic crescentic glomerulonephritis. The Canadian Apheresis Study Group. Am. J. Kidney Dis. (1992) 20:261-269.
   PubMed Web of Science ®Google Scholar
• THYSELL H, BYGREN P, BENGTSSON U et al.: Immunosuppression and the additive effect of plasma exchange in treatment of rapidly progressive glomerulonephritis. Acta Med. Scand. (1982) 212:107-114.
   PubMed Web of Science ®Google Scholar
• GLOCKNER WM, SIEBERTH HG, WICHMANN HE et al.: Plasma exchange and immunosuppression in rapidly progressive glomerulonephritis: a controlled, multi-center study. Clin. Nephrol. (1988) 29:1-8.
   PubMed Web of Science ®Google Scholar
• GASKIN G, PUSEY CD: Plasmapheresis in antineutrophil cytoplasmic antibody-associated systemic vasculitis. Ther. Apher. (2001) 5:176-181.
   PubMedGoogle Scholar
• YAMAGATA K, HIRAYAMA K, MASE K et al.: Apheresis for MPO-ANCA-associated RPGN-indications and efficacy: lessons learned from Japan nationwide survey of RPGN. J. Clin. Apher. (2005) 20:244-251.
   PubMed Web of Science ®Google Scholar
• PUSEY CD, REES AJ, EVANS DJ, PETERS DK, LOCKWOOD CM: Plasma exchange in focal necrotizing glomerulonephritis without anti-GBM antibodies. Kidney Int. (1991) 40:757-763.
   PubMed Web of Science ®Google Scholar
• FRASCA GM, SOVERINI ML, FALASCHINI A, TAMPIERI E, VANGELISTA A, STEFONI S: Plasma exchange treatment improves prognosis of antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis: a case-control study in 26 patients from a single center. Ther. Apher. Dial. (2003) 7:540-546.
   PubMed Web of Science ®Google Scholar
• GUILLEVIN L, CEVALLOS R, DURAND-GASSELIN B, LHOTE F, JARROUSSE B, CALLARD P: Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann. Med. Intern. (Paris) (1997) 148:198-204.
   PubMedGoogle Scholar
• GASKIN G, JAYNE D: Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis. J. Am. Soc. Nephrol. (2002) 13:2A (Abstract).
   Web of Science ®Google Scholar
• JAYNE DR, CHAPEL H, ADU D et al.: Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM (2000) 93:433-439.
   PubMed Web of Science ®Google Scholar
• LEVY JB, PUSEY CD: Nephrotoxicity of intravenous immunoglobulin. QJM (2000) 93:751-755.
   PubMed Web of Science ®Google Scholar
• Renal insufficiency and failure associated with immune globulin intravenous therapy – United States, 1985 – 1998. MMWR Morb. Mortal. Wkly Rep. (1999) 48:518-521.
   PubMedGoogle Scholar
• ORBACH H, TISHLER M, SHOENFELD Y: Intravenous immunoglobulin and the kidney – a two-edged sword. Semin. Arthritis Rheum. (2004) 34:593-601.
   PubMed Web of Science ®Google Scholar
• GHEZ D, WESTEEL PF, HENRY I, PRUNA A, FOURNIER A, LASSOUED K: Control of a relapse and induction of long-term remission of Wegener’s granulomatosis by cyclosporine. Am. J. Kidney Dis. (2002) 40:E6.
   Google Scholar
• HAUBITZ M, KOCH KM, BRUNKHORST R: Cyclosporin for the prevention of disease reactivation in relapsing ANCA-associated vasculitis. Nephrol. Dial. Transplant. (1998) 13:2074-2076.
   PubMed Web of Science ®Google Scholar
• BOLTON WK: Goodpasture’s syndrome. Kidney Int. (1996) 50:1753-1766.
   PubMed Web of Science ®Google Scholar
• TAM FWK, SMITH J, MOREL D et al.: Development of scarring and renal failure in a rat model of crescentic glomerulonephritis. Nephrol. Dial. Transplant. (1999) 14:1658-1666.
   PubMed Web of Science ®Google Scholar
• KAWASAKI K, YAOITA E, YAMAMOTO T, KIHARA I: Depletion of CD8 positive cells in nephrotoxic serum nephritis of WKY rats. Kidney Int. (1992) 41:1517-1526.
   PubMed Web of Science ®Google Scholar
• REYNOLDS J, NORGAN VA, BHAMBRA U, SMITH J, COOK HT, PUSEY CD: Anti-CD8 monoclonal antibody therapy is effective in the prevention and treatment of experimental autoimmune glomerulonephritis. J. Am. Soc. Nephrol. (2002) 13:359-369.
   PubMed Web of Science ®Google Scholar
• LEVY JB, TURNER AN, REES AJ, PUSEY CD: Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann. Intern. Med. (2001) 134:1033-1042.
   PubMed Web of Science ®Google Scholar
• BOSCH X, MIRAPEIX E, FONT J et al.: Prognostic implication of anti-neutrophil cytoplasmic autoantibodies with myeloperoxidase specificity in anti-glomerular basement membrane disease. Clin. Nephrol. (1991) 36:107-113.
   PubMed Web of Science ®Google Scholar
• LEVY JB, HAMMAD T, COULTHART A, DOUGAN T, PUSEY CD: Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. (2004) 66:1535-1540.
   PubMed Web of Science ®Google Scholar
• ABE T, KIDA H, YOSHIMURA M et al.: Participation of extracapillary lesions (ECL) in progression of IgA nephropathy. Clin. Nephrol. (1986) 25:37-41.
   PubMed Web of Science ®Google Scholar
• BARRATT J, FEEHALLY J: Treatment of IgA nephropathy. Kidney Int. (2006) 69:1934-1938.
   PubMed Web of Science ®Google Scholar
• TUMLIN JA, LOHAVICHAN V, HENNIGAR R: Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide. Nephrol. Dial. Transplant. (2003) 18:1321-1329.
   PubMed Web of Science ®Google Scholar
• FERRARIO F, NAPODANO P, RASTALDI MP, D’AMICO G: Capillaritis in IgA nephropathy. Contrib. Nephrol. (1995) 111:8-12.
   PubMedGoogle Scholar
• McINTYRE CW, FLUCK RJ, LAMBIE SH: Steroid and cyclophosphamide therapy for IgA nephropathy associated with crescenteric change: an effective treatment. Clin. Nephrol. (2001) 56:193-198.
   PubMed Web of Science ®Google Scholar
• COPPO R, BASOLO B, GIACHINO O et al.: Plasmapheresis in a patient with rapidly progressive idiopathic IgA nephropathy: removal of IgA-containing circulating immune complexes and clinical recovery. Nephron (1985) 40:488-490.
   PubMedGoogle Scholar
• LAI KN, LAI FM, LEUNG AC, HO CP, VALLANCE-OWEN J: Plasma exchange in patients with rapidly progressive idiopathic IgA nephropathy: a report of two cases and review of literature. Am. J. Kidney Dis. (1987) 10:66-70.
   PubMedGoogle Scholar
• CHAMBERS ME, McDONALD BR, HALL FW, RABETOY GM: Plasmapheresis for crescentic IgA nephropathy: a report of two cases and review of the literature. J. Clin. Apher. (1999) 14:185-187.
   PubMed Web of Science ®Google Scholar
• ROY S III, MURPHY WM, ARANT BS Jr: Poststreptococcal crescenteric glomerulonephritis in children: comparison of quintuple therapy versus supportive care. J. Pediatr. (1981) 98:403-410.
   PubMed Web of Science ®Google Scholar
• RAFF A, HEBERT T, PULLMAN J, COCO M: Crescentic post-streptococcal glomerulonephritis with nephrotic syndrome in the adult: is aggressive therapy warranted? Clin. Nephrol. (2005) 63:375-380.
   PubMed Web of Science ®Google Scholar
• CONNOLLY CE, GALLAGHER B: Acute crescentic glomerulonephritis as a complication of a Staphylococcus aureus abscess of hip joint prosthesis. J. Clin. Pathol. (1987) 40:1486.
   PubMedGoogle Scholar
• KOBAYASHI M, KOYAMA A: Methicillin-resistant Staphylococcus aureus (MRSA) infection in glomerulonephritis – a novel hazard emerging on the horizon. Nephrol. Dial. Transplant. (1998) 13:2999-3001.
   PubMed Web of Science ®Google Scholar
• NAGABA Y, HIKI Y, AOYAMA T et al.: Effective antibiotic treatment of methicillin-resistant Staphylococcus aureus-associated glomerulonephritis. Nephron (2002) 92:297-303.
   PubMed Web of Science ®Google Scholar
• ROVZAR MA, LOGAN JL, OGDEN DA, GRAHAM AR: Immunosuppressive therapy and plasmapheresis in rapidly progressive glomerulonephritis associated with bacterial endocarditis. Am. J. Kidney Dis. (1986) 7:428-433.
   PubMed Web of Science ®Google Scholar
• DAIMON S, MIZUNO Y, FUJII S et al.: Infective endocarditis-induced crescentic glomerulonephritis dramatically improved by plasmapheresis. Am. J. Kidney Dis. (1998) 32:309-313.
   PubMed Web of Science ®Google Scholar
• COUZI L, MOREL D, DEMINIERE C, MERVILLE P: An unusual endocarditis-induced crescentic glomerulonephritis treated by plasmapheresis. Clin. Nephrol. (2004) 62:461-464.
   PubMed Web of Science ®Google Scholar
• HUANG Y, LIU Z, HUANG H, LIU H, LI L: Effects of mycophenolic acid on endothelial cells. Int. Immunopharmacol. (2005) 5:1029-1039.
   PubMed Web of Science ®Google Scholar
• SHERYANNA AM, SMITH J, PUSEY CD, COOK HT: Mycophenolate mofetil (MMF) ameliorates acute inflammation and attenuates scarring in a model of crescentic glomerulonephritis in WKY rats. J. Am. Soc. Nephrol. (2004) 15:688A (Abstract).
   Google Scholar
• TAKEDA S, TAKAHASHI M, SADO Y et al.: Prevention of glomerular crescent formation in glomerulonephritis by mycophenolate mofetil in rats. Nephrol. Dial. Transplant. (2004) 19:2228-2236.
   PubMed Web of Science ®Google Scholar
• JOY MS, HOGAN SL, JENNETTE JC, FALK RJ, NACHMAN PH: A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. Nephrol. Dial. Transplant. (2005) 20:2725-2732.
   Web of Science ®Google Scholar
• NOWACK R, GOBEL U, KLOOKER P, HERGESELL O, ANDRASSY K, VAN DER WOUDE FJ: Mycophenolate mofetil for maintenance therapy of Wegener’s granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J. Am. Soc. Nephrol. (1999) 10:1965-1971.
   PubMed Web of Science ®Google Scholar
• LANGFORD CA, TALAR-WILLIAMS C, SNELLER MC: Mycophenolate mofetil for remission maintenance in the treatment of Wegener’s granulomatosis. Arthritis Rheum. (2004) 51:278-283.
   PubMed Web of Science ®Google Scholar
• BORROWS R, CHUSNEY G, LOUCAIDOU M et al.: Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am. J. Transplant. (2006) 6:121-128.
   PubMed Web of Science ®Google Scholar
• GARCIA-CANTON C, TOLEDO A, PALOMAR R et al.: Goodpasture’s syndrome treated with mycophenolate mofetil. Nephrol. Dial. Transplant. (2000) 15:920-922.
   PubMed Web of Science ®Google Scholar
• FRISCH G, LIN J, ROSENSTOCK J et al.: Mycophenolate mofetil (MMF) versus placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol. Dial. Transplant. (2005) 20:2139-2145.
   PubMed Web of Science ®Google Scholar
• MAES BD, OYEN R, CLAES K et al.: Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int. (2004) 65:1842-1849.
   PubMed Web of Science ®Google Scholar
• TANG S, LEUNG JC, CHAN LY et al.: Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. (2005) 68:802-812.
   PubMed Web of Science ®Google Scholar
• METZLER C, FINK C, LAMPRECHT P, GROSS WL, REINHOLD-KELLER E: Maintenance of remission with leflunomide in Wegener’s granulomatosis. Rheumatology (Oxford) (2004) 43:315-320.
   PubMed Web of Science ®Google Scholar
• HAGEN EC, DE KEIZER RJ, ANDRASSY K et al.: Compassionate treatment of Wegener’s granulomatosis with rabbit anti-thymocyte globulin. Clin. Nephrol. (1995) 43:351-359.
   PubMed Web of Science ®Google Scholar
• SCHMITT WH, HAGEN EC, NEUMANN I, NOWACK R, FLORES-SUAREZ LF, VAN DER WOUDE FJ: Treatment of refractory Wegener’s granulomatosis with antithymocyte globulin (ATG): an open study in 15 patients. Kidney Int. (2004) 65:1440-1448.
   PubMed Web of Science ®Google Scholar
• NADLER LM, ANDERSON KC, MARTI G et al.: B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J. Immunol. (1983) 131:244-250.
   PubMed Web of Science ®Google Scholar
• REFF ME, CARNER K, CHAMBERS KS et al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 83:435-445.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, WHITE CA et al.: IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s lymphoma. Blood (1997) 90:2188-2195.
   PubMed Web of Science ®Google Scholar
• ERIKSSON P: Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J. Intern. Med. (2005) 257:540-548.
   PubMed Web of Science ®Google Scholar
• KEOGH KA, WYLAM ME, STONE JH, SPECKS U: Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. (2005) 52:262-268.
   PubMed Web of Science ®Google Scholar
• ARZOO K, SADEGHI S, LIEBMAN HA: Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann. Rheum. Dis. (2002) 61:922-924.
   PubMed Web of Science ®Google Scholar
• TIMOSHANKO JR, SEDGWICK JD, HOLDSWORTH SR, TIPPING PG: Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis. J. Am. Soc. Nephrol. (2003) 14:1785-1793.
   PubMed Web of Science ®Google Scholar
• KARKAR AM, TAM FWK, STEINKASSERER A et al.: Modulation of antibody-mediated glomerular injury in vivo by IL-1ra, soluble IL-1 receptor and soluble TNF receptor. Kidney Int. (1995) 48:1738-1746.
   PubMed Web of Science ®Google Scholar
• TAM FWK, KARKAR AM, SMITH J et al.: Differential expression of macrophage inflammatory protein-2 and monocyte chemoattractant protein-1 in experimental glomerulonephritis. Kidney Int. (1996) 49:715-721.
   PubMed Web of Science ®Google Scholar
• KARKAR AM, SMITH J, PUSEY CD: Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor α. Nephrol. Dial. Transplant (2001) 16:518-524.
   PubMed Web of Science ®Google Scholar
• KHAN SB, COOK HT, BHANGAL G, SMITH J, TAM FW, PUSEY CD: Antibody blockade of TNF-α reduces inflammation and scarring in experimental crescentic glomerulonephritis. Kidney Int. (2005) 67:1812-1820.
   PubMed Web of Science ®Google Scholar
• BOOTH A, HARPER L, HAMMAD T et al.: Prospective study of TNFα blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. (2004) 15:717-721.
   PubMed Web of Science ®Google Scholar
• THE WEGENER’S GRANULOMATOSISETANERCEPT TRIAL (WGET) RESEARCH GROUP: Etanercept plus standard therapy for Wegener’s granulomatosis. N. Engl. J. Med. (2005) 352:351-361.
   PubMed Web of Science ®Google Scholar
• LUGERING A, SCHMIDT M, LUGERING N, PAUELS HG, DOMSCHKE W, KUCHARZIK T: Infliximab induces apoptosis in monocytes from patients with chronic active Crohn’s disease by using a caspase-dependent pathway. Gastroenterology (2001) 121:1145-1157.
   PubMed Web of Science ®Google Scholar
• GUDBRANDSDOTTIR S, LARSEN R, SORENSEN LK et al.: TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis. Clin. Exp. Rheumatol. (2004) 22:118-124.
   PubMed Web of Science ®Google Scholar
• GUPTA RK, BALOGUN RA: Native renal biopsies: complications and glomerular yield between radiologists and nephrologists. J. Nephrol. (2005) 18:553-558.
   PubMed Web of Science ®Google Scholar
• TAM FWK, SANDERS J-S, GEORGE A et al.: Urinary monocyte chemoattractant protein-1 (MCP-1) is a marker of active renal vasculitis. Nephrol. Dial. Transplant. (2004) 19:2761-2768.
   PubMed Web of Science ®Google Scholar
• GOUMENOS DS, KALLIAKMANI P, TSAKAS S, SOTSIOU F, VLACHOJANNIS JG: Urinary transforming growth factor-β1 as a marker of response to immunosuppressive treatment, in patients with crescentic nephritis. BMC Nephrol. (2005) 6:16.
   PubMedGoogle Scholar
• LIGHTSTONE L, MOSLEY K, EDWARDS RJ, CROZIER J, PUSEY CD, TAM FWK: Urinary proteomics profiles are able to discriminate between active and inactive lupus nephritis. J. Am. Soc. Nephrol. (2005) 16:8A (Abstract).
   Web of Science ®Google Scholar
• REYNOLDS J, TAM FWK, CHANDRAKER A et al.: CD28-B7 blockade prevents the development of experimental autoimmune glomerulonephritis. J. Clin. Invest. (2000) 105:643-651.
   PubMed Web of Science ®Google Scholar
• KREMER JM, WESTHOVENS R, LEON M et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. (2003) 349:1907-1915.
   PubMed Web of Science ®Google Scholar
• KAWASAKI K, YAOITA E, YAMAMOTO T, TAMATANI T, MIYASAKA M, KIHARA I: Antibodies against intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 prevent glomerular injury in rat experimental crescentic glomerulonephritis. J. Immunol. (1993) 150:1074-1083.
   PubMed Web of Science ®Google Scholar
• WADA T, YOKOYAMA H, FURUICHI K et al.: Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1). FASEB J. (1996) 10:1418-1425.
   PubMedGoogle Scholar
• GARCIA GE, XIA Y, HARRISON J et al.: Mononuclear cell-infiltrate inhibition by blocking macrophage-derived chemokine results in attenuation of developing crescentic glomerulonephritis. Am. J. Pathol. (2003) 162:1061-1073.
   PubMed Web of Science ®Google Scholar
• FENG L, CHEN S, GARCIA GE et al.: Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid communication. Kidney Int. (1999) 56:612-620.
   PubMed Web of Science ®Google Scholar
• COOK HT, KHAN SB, ALLEN A et al.: Treatment with an antibody to VLA-1 integrin reduces glomerular and tubulointerstitial scarring in a rat model of crescentic glomerulonephritis. Am. J. Pathol. (2002) 161:1265-1272.
   PubMed Web of Science ®Google Scholar
• ZHOU A, UENO H, SHIMOMURA M et al.: Blockade of TGF-β action ameliorates renal dysfunction and histologic progression in anti-GBM nephritis. Kidney Int. (2003) 64:92-101.
   PubMed Web of Science ®Google Scholar
• TIMOSHANKO JR, KITCHING AR, IWAKURA Y, HOLDSWORTH SR, TIPPING PG: Contributions of IL-1β and IL-1α to crescentic glomerulonephritis in mice. J. Am. Soc. Nephrol. (2004) 15:910-918.
   PubMed Web of Science ®Google Scholar
• LAN HY, NIKOLIC PATERSON DJ, MU W, VANNICE JL, ATKINS RC: Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat. Kidney Int. (1995) 47:1303-1309.
   PubMed Web of Science ®Google Scholar
• TAM FWK, SMITH J, KARKAR AM, PUSEY CD, REES AJ: Interleukin-4 ameliorates experimental glomerulo- nephritis and upregulates glomerular gene expression of IL-1 decoy receptor. Kidney Int. (1997) 52:1224-1231.
   PubMed Web of Science ®Google Scholar
• COOK HT, SINGH SJ, WEMBRIDGE DE, SMITH J, TAM FW, PUSEY CD: Interleukin-4 ameliorates crescentic glomerulonephritis in Wistar Kyoto rats. Kidney Int. (1999) 55:1319-1326.
   PubMed Web of Science ®Google Scholar
• GILLEECE MH, SCARFFE JH, GHOSH A et al.: Recombinant human interleukin 4 (IL-4) given as daily subcutaneous injections – a Phase I dose toxicity trial. Br. J. Cancer (1992) 66:204-210.
   PubMed Web of Science ®Google Scholar
• CHADBAN SJ, TESCH GH, LAN HY, ATKINS RC, NIKOLIC-PATERSON DJ: Effect of interleukin-10 treatment on crescentic glomerulonephritis in rats. Kidney Int. (1997) 51:1809-1817.
   PubMed Web of Science ®Google Scholar
• EL-SHEMI AG, FUJINAKA H, MATSUKI A et al.: Suppression of experimental crescentic glomerulonephritis by interleukin-10 gene transfer. Kidney Int. (2004) 65:1280-1289.
   PubMed Web of Science ®Google Scholar
• STAMBE C, NIKOLIC-PATERSON DJ, HILL PA, DOWLING J, ATKINS RC: p38 Mitogen-activated protein kinase activation and cell localization in human glomerulonephritis: correlation with renal injury. J. Am. Soc. Nephrol. (2004) 15:326-336.
   PubMed Web of Science ®Google Scholar
• SHERYANNA AM, BHANGAL G, SMITH J et al.: Treatment with p38 MAPK inhibitor ameliorates experimental crescentic glomerulonephritis. J. Am. Soc. Nephrol. (2004) 15:234A (Abstract).
   PubMed Web of Science ®Google Scholar
• TAM FWK, SMITH J, AGARWAL S et al.: Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis. Nephron (2000) 84:58-66.
   PubMedGoogle Scholar
• SOLLE M, LABASI J, PERREGAUX DG et al.: Altered cytokine production in mice lacking P2X7 receptors. J. Biol. Chem. (2001) 276:125-132.
   PubMed Web of Science ®Google Scholar
• TURNER CM, TAM FWK, LAI PC et al.: Increased expression of the pro-apoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrol. Dial. Transplant. (2006) (In Press).
   PubMedGoogle Scholar